A Phase 2 interventional study of Computed Tomography and Magnetic Resonance Imaging in Recurrent Endometrial Endometrioid Adenocarcinoma, Recurrent Malignant Uterine Corpus Neoplasm and Recurrent Ovarian Carcinoma, sponsored by National Cancer Institute (NCI). Active, not recruiting at 581 sites in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-18.
Sponsored by National Cancer Institute (NCI) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 130 studies in Ovarian Neoplasms by National Cancer Institute (NCI) — 11 open to participants now, 37 under way, 5 of them phase 3. Ovarian Neoplasms · National Cancer Institute (NCI).
Among the 130 studies in Ovarian Neoplasms by National Cancer Institute (NCI), this one is the 45th largest by enrollment of the 104 interventional ones that give a count, is one of 3 that started in 2019, is one of 50 in phase 2, reaches primary completion later than 12 of the 35 other live ones, and was the 107th registered.
3,390 studies on the registry are indexed under Ovarian Neoplasms; 791 are open to participants now.
Browse Ovarian Neoplasms studies →11 of the 130 studies in Ovarian Neoplasms by National Cancer Institute (NCI) are open now, in 2 countries. Recruiting first, the newest first:
National Cancer Institute (NCI) · Sites in United States
Ages 18–120
National Cancer Institute (NCI) · Sites in United States
Ages 18–120
National Cancer Institute (NCI) · Sites in United States
Ages 45–75 · Healthy volunteers
National Cancer Institute (NCI) · Sites in United States, Puerto Rico
National Cancer Institute (NCI) · Sites in United States
Ages 18–120
By country, each count listing its studies:
Of the 602 Ovarian Neoplasms studies recruiting now, 438 (73%) set no upper age limit and 108 (18%) stop at 75 or younger; 39 take children under 18; 46 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
130 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 55 · Phase 2 60 · Phase 3 7
First in 1991; this study’s year is marked. 3 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 62 is above the median of 54 across 2,556 interventional studies indexed under Ovarian Neoplasms.
Median enrollment 52 across the 104 interventional studies, 750 across the 16 observational. Of the 88 that completed or were terminated, 37 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
National Cancer Institute (NCI) is the lead sponsor of 3,557 studies on the registry; 336 are open to participants now.
Of its 412 completed or terminated interventional studies of FDA-regulated products, 374 (91%) have results posted.
2 of the studies in Ovarian Neoplasms by National Cancer Institute (NCI) that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04314401National Cancer Institute (NCI)National Cancer Institute "Cancer Moonshot Biobank" | 2027-04-30 |
| NCT04491942National Cancer Institute (NCI)Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer | 2027-06-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 130 studies in Ovarian Neoplasms by National Cancer Institute (NCI), from their registry updates:
This tab as a report to print or save as PDF → With an account.
This phase II trial studies how well tazemetostat works in treating patients with ovarian or endometrial cancer that has come back (recurrent). Chemotherapy drugs, such as tazemetostat, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
PRIMARY OBJECTIVES:
I. To assess the clinical activity (overall response rate) of tazemetostat in patients with recurrent or persistent endometrioid or clear cell ovarian carcinoma, and patients with recurrent or persistent endometrioid endometrial adenocarcinoma.
II. To assess the clinical activity (response frequency) of tazemetostat in patients with recurrent or persistent clear cell ovarian carcinoma with an ARID1A mutation.
SECONDARY OBJECTIVES:
I. To examine the nature and degree of toxicity in patients with this regimen. II. To examine the progression free survival and overall survival for this patient population receiving tazemetostat.
III. To examine the 6 month clinical benefit rate in patients treated with this regimen. (20-OCT-2021) IV. To evaluate BAF250a expression in patient samples as an indicator of ARID1A mutation status and correlation with the clinical response to study drug. Note: this only applies to patients enrolled prior to the 20-OCT-2021 version date. (20-OCT-2021)
EXPLORATORY OBJECTIVES:
I. Whether or not the patient has an ARID1A mutation. (08/13/2019) Note: this only applies to patients enrolled prior to the 20-OCT-2021 version date. (20-OCT-2021) (Translational Research Integrated Objective) II. To examine the correlation between ARID1A mutation and BAF250a expression and to identify potential mutations predictive of response in patients with preserved BAF250a expression. Note: this only applies to patients enrolled prior to the 20-OCT-2021 version date. (20-OCT-2021)
OUTLINE:
Patients receive tazemetostat orally (PO) twice daily (BID) on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo computed tomography (CT) scans and magnetic resonance imaging (MRI) on study.
After completion of study treatment, patients are followed up every 3 months for 2 years and then every 6 months for 3 years.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Pathologically (histologically or cytologically) proven diagnosis of recurrent or persistent ovarian endometrioid or clear cell carcinoma, OR recurrent or persistent endometrioid endometrial adenocarcinoma; patients with recurrent endometrial cancer must have mismatch repair (MMR) immunohistochemistry completed; if they are found to be mismatch repair deficient, they should be offered treatment with immune checkpoint inhibition before consideration for treatment on trial; primary ovarian tumors must be at least 50% endometrioid or clear cell morphology, or have documented recurrence with at least 50% endometrioid or clear cell morphology; institutional pathology reports must be provided indicating at least 50% endometrioid or clear cell morphology for ovarian tumors (primary or recurrent lesions)
Patients must have completed prior therapy:
Chemotherapy: cytotoxic
Chemotherapy: nitrosoureas
Chemotherapy: non-cytotoxic (e.g. small molecule inhibitor)
Monoclonal antibody(ies)
Immunotherapy
Radiotherapy (RT)
Appropriate stage for study entry based on the following diagnostic workup:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients receive tazemetostat PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT scans and MRI on study.
Procedure: Computed Tomography · Procedure: Magnetic Resonance Imaging · Drug: Tazemetostat
Undergo CT scan
Also known as: CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, Diagnostic CAT Scan, Diagnostic CAT Scan Service Type, tomography
Undergo MRI
Also known as: Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI
Given PO
Also known as: E 7438, E-7438, E7438, EPZ 6438, EPZ-6438, EPZ6438
Tumor Response
Will be defined by Response Evaluation Criteria in Solid Tumors (RECIST) version (v) 1.1. The statistic reported is the response rate (i.e. (total responses / total at risk) \* 100).
Time frame: Up to 6 months
Tumor Response in Patients With ARID1A Mutations Using Tumor Response (Removed as of Version Date 20-OCT-2021)
Will be defined by RECIST v 1.1.
Time frame: Up to 6 months
6-month Progression Free Survival (Clinical Benefit Rate)
Six-month progression free survival (clinical benefit rate). The clinical benefit rate is the total number (or percentage) of patients who had a complete response, or a partial response or who had stable disease for six months or more.
Time frame: Up to 6 months
Number of Patients With a Grade 3 (or Higher) Adverse Events
Will be assessed according to grade of toxicity by organ or organ system. This will be reported by group (Endometrial or Ovarian). This study reported adverse events by CTCAE v5.0.
Time frame: Adverse events were collected for a maximum of 23.5 months (interquartile range: 1.4 months, 3.9 months).
Progression-free Survival
Will be characterized by quartiles and the median of the distribution with confidence intervals. Kaplan-Meier plots will show an estimate of the survival function for these populations.
Time frame: Progression-free survival times were collected for a maximum of 30.0 months (interquartile range: 1.8 months, 5.5 months).
Overall Survival
Will be characterized by quartiles and the median of the distribution with confidence intervals. Kaplan-Meier plots will show an estimate of the survival function for these populations.
Time frame: Overall survival times were collected for a maximum of 51.6 months (interquartile range: 4.3 months, 19.0 months).
ARID1A Mutational Status
ARID1A mutational status was ealuated by MSK-IMPACT.
Time frame: Up to 6 months
BAF250a Expression
BAF250a expression was assessed by immunohistochemistry (IHC) as an indicator of ARID1A mutation status.
Time frame: Up to 6 months
| Milestone | Arm I: Treatment (Tazemetostat) in Endometrial Cancer Patients | Arm II: Treatment (Tazemetostat) Ovarian in Cancer Patients |
|---|---|---|
| Started | 19 | 43 |
| Completed | 16 | 42 |
| Not completed | 3 | 1 |
| Withdrew: Not eligible, no treatment | 0 | 1 |
| Withdrew: Not eligible, treated | 2 | 0 |
| Withdrew: Eligible, no treatment | 1 | 0 |
Will be defined by Response Evaluation Criteria in Solid Tumors (RECIST) version (v) 1.1. The statistic reported is the response rate (i.e. (total responses / total at risk) \* 100).
| Response/Patient (Percentage) | Arm I: Treatment (Tazemetostat) in Endometrial Cancer Patients | Arm II: Treatment (Tazemetostat) Ovarian in Cancer Patients |
|---|---|---|
| Tumor Response | 0 (0 to 15) | 4.7 (0.6 to 15.8) |
Will be defined by RECIST v 1.1.
Results for this outcome have not been posted.
Six-month progression free survival (clinical benefit rate). The clinical benefit rate is the total number (or percentage) of patients who had a complete response, or a partial response or who had stable disease for six months or more.
| Percentage with 6-month PFS | Arm I: Treatment (Tazemetostat) in Endometrial Cancer Patients | Arm II: Treatment (Tazemetostat) Ovarian in Cancer Patients |
|---|---|---|
| 6-month Progression Free Survival (Clinical Benefit Rate) | 25 (7.3 to 52.4) | 19 (8.6 to 34.1) |
Will be assessed according to grade of toxicity by organ or organ system. This will be reported by group (Endometrial or Ovarian). This study reported adverse events by CTCAE v5.0.
| Participants | Arm I: Treatment (Tazemetostat) in Endometrial Cancer Patients | Arm II: Treatment (Tazemetostat) Ovarian in Cancer Patients |
|---|---|---|
| Number of Patients With a Grade 3 (or Higher) Adverse Events | 6 | 20 |
Will be characterized by quartiles and the median of the distribution with confidence intervals. Kaplan-Meier plots will show an estimate of the survival function for these populations.
| months | Arm I: Treatment (Tazemetostat) in Endometrial Cancer Patients | Arm II: Treatment (Tazemetostat) Ovarian in Cancer Patients |
|---|---|---|
| Progression-free Survival | 2.05 (1.84 to 5.49) | 3.04 (2.04 to 4.37) |
Will be characterized by quartiles and the median of the distribution with confidence intervals. Kaplan-Meier plots will show an estimate of the survival function for these populations.
| months | Arm I: Treatment (Tazemetostat) in Endometrial Cancer Patients | Arm II: Treatment (Tazemetostat) Ovarian in Cancer Patients |
|---|---|---|
| Overall Survival | 25.3 (3.8 to NA) | 13.7 (8.0 to 22.4) |
ARID1A mutational status was ealuated by MSK-IMPACT.
| Participants | Arm I: Treatment (Tazemetostat) in Endometrial Cancer Patients | Arm II: Treatment (Tazemetostat) Ovarian in Cancer Patients |
|---|---|---|
| ARID1A Mutational Status | 6 | 9 |
BAF250a expression was assessed by immunohistochemistry (IHC) as an indicator of ARID1A mutation status.
| Participants | Arm I: Treatment (Tazemetostat) in Endometrial Cancer | Arm II: Treatment (Tazemetostat) Ovarian in Cancer Patients |
|---|---|---|
| BAF250a Expression | 12 | 12 |
Collected over Adverse events were collected for a maximum of 23.5 months (interquartile range: 1.4 months, 3.9 months). All-Cause Mortality monitored/assessed up to 51.6 months (interquartile range: 4.3 months, 19.0 months).. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Arm I: Treatment (Tazemetostat) in Endometrial Cancer Patients | 11/16 (68.8%) | 3/16 (18.8%) | 15/16 (93.8%) |
| Arm II: Treatment (Tazemetostat) Ovarian in Cancer Patients | 28/42 (66.7%) | 12/42 (28.6%) | 40/42 (95.2%) |
| Event | Arm I: Treatment (Tazemetostat) in Endometrial Cancer Patients | Arm II: Treatment (Tazemetostat) Ovarian in Cancer Patients |
|---|---|---|
| NauseaGastrointestinal disorders | 2/16 | 3/42 |
| Abdominal painGastrointestinal disorders | 1/16 | 2/42 |
| Colonic obstructionGastrointestinal disorders | 1/16 | 0/42 |
| VomitingGastrointestinal disorders | 1/16 | 0/42 |
| Disease progressionGeneral disorders | 1/16 | 2/42 |
| FatigueGeneral disorders | 1/16 | 0/42 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 1/16 | 0/42 |
| MyalgiaMusculoskeletal and connective tissue disorders | 1/16 | 0/42 |
| AtaxiaNervous system disorders | 1/16 | 0/42 |
| ParesthesiaNervous system disorders | 1/16 | 0/42 |
| Event | Arm I: Treatment (Tazemetostat) in Endometrial Cancer Patients | Arm II: Treatment (Tazemetostat) Ovarian in Cancer Patients |
|---|---|---|
| NauseaGastrointestinal disorders | 6/16 | 23/42 |
| FatigueGeneral disorders | 7/16 | 20/42 |
| AnemiaBlood and lymphatic system disorders | 7/16 | 16/42 |
| DiarrheaGastrointestinal disorders | 6/16 | 9/42 |
| Abdominal painGastrointestinal disorders | 5/16 | 9/42 |
| VomitingGastrointestinal disorders | 3/16 | 13/42 |
| AnorexiaMetabolism and nutrition disorders | 3/16 | 12/42 |
| DyspneaRespiratory, thoracic and mediastinal disorders | 1/16 | 11/42 |
| DysgeusiaNervous system disorders | 4/16 | 6/42 |
| HeadacheNervous system disorders | 4/16 | 4/42 |
All enrolled patients
| Age, Customized(Participants) | Arm I: Treatment (Tazemetostat) in Endometrial Cancer Patients | Arm II: Treatment (Tazemetostat) Ovarian in Cancer Patients | Total |
|---|---|---|---|
| 20-29 years | 0 | 1 | 1 |
| 30-39 years | 0 | 1 | 1 |
| 40-49 years | 0 | 6 | 6 |
| 50-59 years | 5 | 16 | 21 |
| 60-69 years | 11 | 16 | 27 |
| 70-79 years | 1 | 3 | 4 |
| >= 80 years | 2 | 0 | 2 |
| Sex: Female, Male(Participants) | Arm I: Treatment (Tazemetostat) in Endometrial Cancer Patients | Arm II: Treatment (Tazemetostat) Ovarian in Cancer Patients | Total |
|---|---|---|---|
| Female | 19 | 43 | 62 |
| Male | 0 | 0 | 0 |
| Ethnicity (NIH/OMB)(Participants) | Arm I: Treatment (Tazemetostat) in Endometrial Cancer Patients | Arm II: Treatment (Tazemetostat) Ovarian in Cancer Patients | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 2 | 2 |
| Not Hispanic or Latino | 19 | 40 | 59 |
| Unknown or Not Reported | 0 | 1 | 1 |
| Race (NIH/OMB)(Participants) | Arm I: Treatment (Tazemetostat) in Endometrial Cancer Patients | Arm II: Treatment (Tazemetostat) Ovarian in Cancer Patients | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 2 | 2 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 3 | 2 | 5 |
| White | 16 | 37 | 53 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 2 | 2 |
Showing the first 100 of 581 sites. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page
Data sharing details ↗ · grants.nih.gov
Ran from May 2019 to primary completion in Jul 2023, 50 months.
Results were first posted in Mar 2025, 1 year 7 months after primary completion.
Of 228 non-industry phase 2 interventional studies under Ovarian Neoplasms, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 40 and three quarters within 80. This study's 50 months is close to that.
Counting every sponsor, half of 344 studies reached it within 47 months; a quarter within 33 and three quarters within 72.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tazemetostat
National Cancer Institute (NCI) →